IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) — Form 10-K
Reporting period: Fiscal year ended March 31, 2016; comparative period is the year ended March 31, 2015. Although the request metadata refers to “2015 Q4,” this filing is an annual report for fiscal 2016, not a quarterly filing. The company reported consolidated U.S. GAAP results across operations in the United States, Hong Kong, India, China, and Malaysia.
Business context
IGC’s principal reported business was Hong Kong-based trading of electronic components and commodities. It generated 97.2% of fiscal 2016 revenue. The company said it was winding down low-margin trading and shifting resources toward phytocannabinoid-therapy research and intellectual property, indoor-farming infrastructure, and real estate and project management. It acquired Malaysian company Cabaran Ultima in February 2016 and held a 24.9% interest in Midtown Partners.
Financial results and liquidity
| Metric | FY ended Mar. 31, 2016 | FY ended Mar. 31, 2015 |
|---|---|---|
| Revenue | $6.37 million | $7.68 million |
| Gross profit (revenue less cost of revenue) | $0.84 million; approximately 13.2% margin | $0.58 million; approximately 7.5% margin |
| Operating loss | $2.91 million | $4.34 million |
| Net loss attributable to common stockholders | $2.81 million; loss per share $0.17 | $4.61 million; loss per share $0.31 |
| Net cash used in operating activities | $0.16 million | $2.58 million |
| Cash and cash equivalents at year-end | $1.49 million | $0.82 million |
| Total assets / total liabilities | $18.86 million / $4.91 million | $20.33 million / $5.58 million |
- Revenue declined 17.1% year over year, reflecting lower volume and product diversity in electronic-component trading. Trading revenue was $6.25 million; rental, leasing, and real estate revenue was $114,748.
- Cost of revenue fell to $5.52 million from $7.10 million; management reported cost of revenue at approximately 86% of revenue versus 92% in the prior year. SG&A declined 34.7%, to $2.70 million, contributing to the narrower operating loss.
- Other income was $284,186, including a $251,264 gain from a land sale by TBL. Fiscal 2016 also included a $317,510 loss on investments/associates/joint ventures and $728,741 of depreciation, largely associated with non-operating Chinese beneficiation equipment.
- Year-end working capital was approximately $0.64 million. Current assets were $3.84 million and current liabilities $3.20 million. Net investing cash outflow was $183,422; financing provided $1.01 million.
- Total liabilities declined by approximately $0.67 million, but the $1.8 million note payable was classified as current and due July 31, 2016. The company stated the note had no cash interest payable; interest-related payments were made in stock.
- The company reported a non-GAAP cash-burn estimate of approximately $0.86 million after adjustments for non-cash and one-time items; this excludes cash used for investments and construction in progress. It also said its large operating subsidiary was near breakeven.
Changes, outlook, and material risks
- Management attributed the improved operating result mainly to lower SG&A and lower component purchasing costs, while revenue contracted. Shares issued and outstanding increased to 23.27 million from 14.77 million, reflecting equity financing, compensation, and acquisition-related issuances.
- IGC said it had adequate cash for obligations but would need to raise capital to expand. A subsequent May 2016 at-the-market agreement permits up to $10 million in share sales, subject to a 5% sales commission; future issuance could dilute shareholders. No specific revenue or earnings guidance was provided.
- The company had filed five provisional phytocannabinoid patent applications; it reported one pain-therapy application converted to a utility/PCT application, but patent registration and commercial success were not assured. U.S. federal restrictions on cannabis complicate testing and product development; the company deferred U.S. testing and anticipated seeking testing where legally permitted. It estimated FDA-approved human trials could take five to seven years.
- IGC was negotiating an exit from its 51% interest in IGC International and from the trading business. The China Ironman assets, including beneficiation plants that were not operating in fiscal 2016, remain on the balance sheet while IGC pursues litigation seeking rescission of the acquisition; trial was anticipated in mid-2017. The outcome could materially affect reported assets and additional paid-in capital.
- The approximately $5.18 million Nagpur land investment reflects a settlement for IGC’s former minority interest in Sricon; the land was registered in IGC’s name in March 2016. The valuation and recoverability of this asset are important given its materiality.
- Other items requiring attention include $421,588 of aged Cochin International Airport receivables outstanding for more than a year, and an awarded construction claim of about $0.47 million that management expected to collect. The filing also describes a Midtown-related $125,000 amount owed by Apogee and shares subject to cancellation, with settlement discussions ongoing.
- The independent auditor issued an unqualified opinion on the financial statements. Management stated disclosure controls and internal control over financial reporting were effective, while the risk disclosures also cite insufficient personnel with U.S. GAAP and SEC-reporting expertise and the possibility of material weaknesses. This tension merits review.
Most important facts for investors to verify
- Whether IGC repaid, refinanced, or otherwise resolved the $1.8 million note due July 31, 2016, and the terms of any subsequent financing.
- Cash actually available to the parent versus cash held by foreign subsidiaries; the filing reported $611,831 held abroad and said Indian repatriation required regulatory clearance.
- Whether the Nagpur land’s stated value is supported by current independent valuation and whether it can be monetized as expected.
- Progress and accounting consequences of the Ironman litigation, including the status and recoverable value of the currently non-operating Chinese assets.
- Collection of aged and awarded receivables, including the $421,588 Cochin Airport balance, and resolution of the Midtown/Apogee dispute.
- Actual progress in exiting low-margin trading, developing replacement revenue sources, and obtaining patent, regulatory, and capital-market approvals; dilution from further share issuance.